Alvotech (ALVO) On FDA Clearance And Lotus Deal As Undervalued Narrative Gains Ground

Alvotech (NasdaqGM:ALVO) is back on investors’ radar after the FDA voluntarily closed its inspection of the company’s Iceland manufacturing facility, along with a new licensing and commercialization agreement with Lotus Pharmaceutical.

Alvotech’s recent licensing deal and the FDA inspection closure have come alongside sharp short term share price momentum, with a 7 day share price return of 27.85% and a 30 day share price return of 65.03%. However, the 1 year total shareholder return is still down 37.81%, which shows that recent optimism follows a much tougher longer term experience for shareholders.

Spot fresh momentum stories like Alvotech by scanning our hand picked 18 high quality undiscovered gems, which feature strong fundamentals but are still flying under most investors’ radar.

Alvotech’s pipeline, partnerships and fresh guidance paint the picture of a busy biosimilar platform company. After a sharp rebound in the share price, the next step is to see how that story lines up with today’s valuation.

Most Popular Narrative: 12.2% Undervalued

Alvotech’s most followed narrative puts fair value at $5.75 per share, compared with the last close at $5.05, which suggests room between price and expectations.

Ongoing launch and approval pipeline activity, including upcoming regulatory decisions in major global markets (for AVT03, AVT05, AVT23, and others), positions the company to tap into blockbuster biologic markets coming off-patent, potentially driving a step-change in topline revenue once approvals are secured.

Read the complete narrative. Read the complete narrative.

The fair value call hangs on a detailed playbook for Alvotech. It focuses on revenue compounding, margin expansion and a future earnings multiple that is lower than many current peers. It explores which mix of growth, profitability and discount rate assumptions need to line up for $5.75 to make sense on an 8.88% hurdle rate and multi year forecasts.

Result: Fair Value of $5.75 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to weigh two key risks for Alvotech: heavy reliance on unpredictable milestone payments and a sizeable debt load that could pressure future flexibility.

Find out about the key risks to this Alvotech narrative.

Next Steps

If this mix of risks and rewards around Alvotech feels finely balanced, move quickly to review the details and decide where you stand using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Alvotech?

Do not stop with Alvotech. Use this momentum as a springboard to size up other opportunities and avoid missing stocks that quietly fit your checklist.

• Spot potential value opportunities early by scanning our hand picked 49 high quality undervalued stocks while prices still look reasonable.
• Strengthen the defensive side of your portfolio by checking companies in the 74 resilient stocks with low risk scores that score well on resilience.
• Prioritise financial robustness by focusing on stocks from the list of solid balance sheet and fundamentals (51 results) that combine balance sheet strength with sound fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com